Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 90: human papillomaviruses. Lyon: International Agency for Research on Cancer, in press. Iftner, 2003, Chapter 12: human papillomavirus technologies, J Natl Cancer Inst Monogr, 31, 80, 10.1093/oxfordjournals.jncimonographs.a003487 Molijn, 2005, Molecular diagnosis of human papillomavirus (HPV) infections, J Clin Virol, 32, S43, 10.1016/j.jcv.2004.12.004 Snijders, 2003, The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity, J Pathol, 201, 1, 10.1002/path.1433 Gravitt, 2005, Diagnosis and management of oncogenic cervical human papillomavirus infection, Infect Dis Clin North Am, 19, 439, 10.1016/j.idc.2005.03.008 Jacobs, 1999, Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison, J Clin Pathol, 52, 498, 10.1136/jcp.52.7.498 Quint, 2006, Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA, J Clin Microbiol, 44, 571, 10.1128/JCM.44.2.571-579.2006 Munoz, 2004, Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int J Cancer, 111, 278, 10.1002/ijc.20244 Clifford, 2003, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, Br J Cancer, 88, 63, 10.1038/sj.bjc.6600688 Clifford, 2003, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, Br J Cancer, 89, 101, 10.1038/sj.bjc.6601024 Smith JS, Lindsay L, Keys J, Hoots B, Winer R, Franceschi S, et al. HPV type distribution in invasive cervical cancer and high-grade cervical neoplasia: an update of meta-analyses and identification of global data gaps. Br J Cancer, submitted. Clifford, 2005, Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer, Cancer Epidemiol Biomarkers Prev, 14, 1157, 10.1158/1055-9965.EPI-04-0812 Grce, 2001, Evaluation of genital human papillomavirus infections by polymerase chain reaction among Croatian women, Anticancer Res, 21, 579 Voglino, 2000, The role of human papillomavirus in cyto-histological practice: distribution and prevalence of high-risk strains (16, 18, 31, 33, and 35) in intraepithelial lesions and neoplasia of the uterine cervix, Pathologica, 92, 516 ASCUS and LSIL Triage Study Group, 2003, Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance, Am J Obstet Gynecol, 188, 1383, 10.1016/S0002-9378(03)00418-6 Castle, 2005, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst, 97, 1066, 10.1093/jnci/dji186 Herrero, 2005, Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica, J Infect Dis, 191, 1796, 10.1086/428850 Depuydt, 2003, Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women, Br J Cancer, 88, 560, 10.1038/sj.bjc.6600756 Clifford, 2005, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, Lancet, 366, 991, 10.1016/S0140-6736(05)67069-9 Franceschi, 2005, Re: a study of the impact of adding HPV types to cervical cancer screening and triage tests, J Natl Cancer Inst, 97, 938, 10.1093/jnci/dji159 Khan, 2005, The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 97, 1072, 10.1093/jnci/dji187 Brown, 2002, Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic, Sex Transm Dis, 29, 763, 10.1097/00007435-200212000-00005 Strickler, 2003, Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women, J Natl Cancer Inst, 95, 1062, 10.1093/jnci/95.14.1062 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol, 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Harper, 2006, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, Lancet, 367, 1247, 10.1016/S0140-6736(06)68439-0 Ferlay, 2004